DZD Wins Disruptive Technology Award at the 2021 AACC Annual Scientific Meeting
September 30 2021
Award Highlights the Promise of the Company’s New Class of Diagnostics
Read More
DZD Doubles Down on epiXact® Service for Investigating HAI Outbreaks Supported by New NIH Funding Award
December 9 2020
SBIR Phase I Funds to Boost Speed of the Company’s Robust Sequencing and Analysis Service for Infection Control Professionals
Read More
DZD Announces High-Caliber Additions to Leadership Team and Advisory Board
November 17 2020
Dekel Gelbman joins as SVP, Business Development & Strategy, Robin Patel, M.D. joins DZD's clinical and scientific advisory board and Sally Hojvat, Ph.D. joins as a regulatory strategy advisor
Read More
Day Zero Diagnostics Moves Headquarters to SmartLabs at Boston Landing
August 3 2020
Company now occupies over 9,000 square feet of cutting-edge office and lab space
Read More
DZD Announces Positive Data from Multiple Studies Demonstrating Promise of New Technology
October 21 2020
Initial results show new class of diagnostics can provide culture-free pathogen identification and drug-resistance profile within hours, not days
Read More
DZD Research Highlighted in Two Publications on Plasmid-Mediated Antibiotic Resistance
June 2 2020
DZD technical expertise enables identification of novel mechanisms of antibiotic resistance using nanopore sequencing
Read More